Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients
Cancer Medicine · 2025
DOI: 10.1002/cam4.70896 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Soufyan Annakib und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, CHU Nîmes, Univ Montpellier, Nîmes, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Patient Reported Outcome Measures, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre Hospitalier Universitaire de Nîmes.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) improved survival in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Patient‐reported symptoms in this context were poorly studied. The study aimed to compare symptom severity between patients and clinicians. Methodology The secondary analysis of the AMI clinical trial comparing changes in the gut microbiota in patients with la/mUC treated with pembrolizumab was conducted in nine French centers. Secondary endpoints were expected in this prospective study. Patient‐Reported Outcome‐Common Terminology Criteria for Adverse Events (PRO‐CTCAE) and CTCAE were assessed respectively by patients and clinicians before pembrolizumab initiation, and at each treatment visit until treatment cycle 12. Agreement in severity between clinicians and patients for grade ≥ 3 symptoms was calculated with Cohen's kappa coefficient. The toxicity index was generated for CTCAE and PRO‐CTCAE to assess discordance in a longitudinal manner. The Wilcoxon test was used to compare clinicians' and patients' toxicity index and symptom severity frequencies.
Results
Thirty‐nine patients were included (M/F sex ratio: 2.5) from December 2020 to March 2022. PRO‐CTCAE baseline completion rate was 77.5%. Cohen's kappa coefficient ranged from −0.017 (95% confidence interval (CI), [−0.039, 0.005]) for numbness/tingling to 0.161 (95% CI, [0.045, 0.276]) for fatigue. The patient self‐rated symptom toxicity index was > 2 for all symptoms compared to ≤ 0.62 (fatigue) when assessed by clinicians in longitudinal reporting of symptom frequency and severity with a p value < 0.001. The three most commonly reported symptoms by patients and clinicians, respectively, were: Fatigue 53.3% versus 23.4%, generalized pain 42.4% versus 16.5%, and insomnia 41.1% versus 9.5%. Symptom frequency reports between clinicians and patients were statistically different ( p < 0.009).
Conclusions
Symptom severity assessment showed discordance between patients and physicians. Clinicians reported fewer symptoms and graded them less severely than patients. PROs should be used to accurately reflect patient experience. Trial Registration ClinicalTrials.gov identifier: NCT04566029
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, CHU Nîmes, Univ Montpellier, Nîmes, France.
- Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ Montpellier, Nîmes, France.
- University of Montpellier, UMR INSERM IDESP-Desbrest Institute of Epidemiology and Public, Montpellier, France.
- Medical Oncology Department, Institut Bergonié, Bordeaux, France.
- Medical Oncology Department, Institut de cancérologie Lucien Neuwirth, Saint-Etienne, France.
- Medical Oncology Department, Centre Antoine Lacassagne, Université Côte D'azur, Nice, France.
ORCID-Profile: Soufyan Annakib
Förderung
- Centre Hospitalier Universitaire de Nîmes
Zitieren
APA
Annakib, S., Di Méglio, E., Dibert-Bekoy, Y., Chevallier, T., Roubaud, G., Fournel, P., Guillot, A., Borchiellini, D., Pouessel, D., Boughalem, E., Delva, R., Barthelemy, P., Oudard, S., Thibault, C., Tosi, D., Houédé, N., & Fiteni, F. (2025). Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients. Cancer Medicine. https://doi.org/10.1002/cam4.70896
Vancouver
Annakib S, Di Méglio E, Dibert-Bekoy Y, Chevallier T, Roubaud G, Fournel P, et al. Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients. Cancer Medicine. 2025. doi:10.1002/cam4.70896
BibTeX
@article{Annakib2025,
author = {Annakib, Soufyan and Di Méglio, Emma and Dibert-Bekoy, Yona and Chevallier, Thierry and Roubaud, Guilhem and Fournel, Pierre and Guillot, Aline and Borchiellini, Delphine and Pouessel, Damien and Boughalem, Elouen and Delva, Remy and Barthelemy, Philippe and Oudard, Stéphane and Thibault, Constance and Tosi, Diego and Houédé, Nadine and Fiteni, Frédéric},
title = {Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70896}
}
EUVIMED